VIVS

VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool integrates its proprietary NAMkind™ ileum and colon tissues with advanced machine‑learning analytics to identify drug‑induced disruptions to intestinal epithelial integrity and function. Tissue-based assay data is used to train an AI predictive model in a process VivoSim has named VitroSense™. The model was built using a training set of dozens of compounds. Using high-quality real-world 3d NAM assay results generated from the set of training compounds, the model attained a predictive accuracy of 96% for potential diarrhea. This success represents a significant step forward for the field, demonstrating the value of combining data from VivoSim’s complex 3D cell-based assays with machine learning approaches. For a novel compound being investigated for the first time, such as from a client, multiple data endpoints are measured in NAMkind™ intestine assays and these data are fed into the AI prediction model to generate an overall assessment of diarrhea risk. Because so many cancer drugs have dose-limiting toxicities, the Company believes that this breakthrough over reliance on animal models can have a transformational impact on the next generation of cancer treatments. VitroSense™ – the use of NAMkind™-produced data to train predictive machine learning models Central to the concept of use of NAMkind™ models in this way is its integration with its proprietary VitroSense™ toolkit that generates trained machine language models using data from its highly relevant human cell NAMkind™ tissues. “The high biological fidelity of NAMkind™ models allows us to generate data in line with what is seen in humans” said Keith Murphy, VivoSim Executive Chairman. “By using that high-quality data to train AI models, we get much more accurate predictions. You’ve heard of “garbage in, garbage out”, but our models are the opposite: Golden raw data from NAMkind™ tissue assays is fed to the VitroSense™ model and spun into solid gold predictions for our clients’ compounds.” NAMkind™ intestine models allow for mimicking oral or IV administration route, and are excellent for antibody drug conjugate testing. Because of the advanced nature of the NAMkind™ intestinal model, the multilayered structure can be dosed either by mimicking oral administration or intravenous administration by exposing the relevant portion of the tissue – the epithelial lining or the stromal layer. As recently demonstrated at Society of Toxicology, NAMkind™ intestine models were also tested with antibody-drug conjugates (ADCs) and have the ability to detect differential effects such as antibody activity on epithelium, payload impact on epithelium, and overall ADC impact on epithelium. Permeability endpoints are sensitive to the exact chemical compound, be it ADC, antibody alone, or payload. “With 96% prediction accuracy, we believe our intestinal model is world class,” said Amar Sethi, Chief Scientific Officer of VivoSim. “It has the ability to weed out novel compounds with toxic liabilities from those compounds that would survive rigorous clinical trials.” VivoSim is now working with clients to provide an effective screen for effects on the intestinal epithelium for oncology ADC candidates. NAMKind™ liver and small intestine toxicology services are now available in US, Europe, and via local distributor engagement across Korea and China, with VivoSim continuing to scale capacity to support expanding global demand and urgent, real-world development needs. About VivoSim Labs VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMKind™, including target turnaround time and its potential to help users de-risk their pipelines, avoid costly downstream failures, reduce rework, prioritize the right assets, move faster, save millions and reduce risk; VivoSim’s commercial presence across Asia-Pacific; the evaluation and acceptance of scientifically robust NAM-based evidence; the Company’s ability to capture growing demand in the in vitro toxicology testing market; demand for human-relevant toxicology; the market opportunity and market size of gastrointestinal in vitro models and toxicology services; and the Company’s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 11, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. Contact(s): Investor Relations [email protected] VivoSim Labs, Inc.

SHANGHAI, Feb. 05, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced a profit alert for the fourth quarter of 2025. The board of directors of the Company (the “Board”) wishes to inform shareholders and potential investors that, based on a preliminary assessment of the Company’s unaudited consolidated management accounts and the information currently available to the Board, the Company is expected to achieve an adjusted profit from operations (non-GAAP) in the range of approximately RMB700 million (approximately US$100 million)i to RMB1,200 million (approximately US$172 million) for the fourth quarter of 2025, which is defined as profit from operations excluding share-based compensation expenses, representing the first time the Company has recorded an adjusted profit from operations (non-GAAP) on a quarterly basis. In comparison, the Company recorded an adjusted loss from operations (non-GAAP) of RMB5,543.6 million in the fourth quarter of 2024. The expected adjusted profit from operations (non-GAAP) for the fourth quarter of 2025 was primarily attributable to (i) the Company’s sustained growth in sales volume in the fourth quarter of 2025; (ii) the optimization of vehicle margin driven by a favorable product mix; and (iii) the Company’s ongoing comprehensive cost reduction efforts and continued improvement in operational efficiency. In addition, under the GAAP measures, the Company is expected to record a profit from operations of approximately RMB200 million (approximately US$29 million) to RMB700 million (approximately US$100 million) for the fourth quarter of 2025. As of the date of this press release, the Company is in the process of preparing and finalizing the financial results for the three months and full year ended December 31, 2025 (the “Q4 and FY2025 Results”). The information contained in this press release is only based on a preliminary review of the unaudited consolidated management accounts and the information currently available to the Board, and is not based on any figures or information which have been audited or reviewed by the Company’s independent auditor or the audit committee of the Board. The above data may therefore differ from the figures to be disclosed in the audited or unaudited consolidated financial statements in respect of the Q4 and FY2025 Results. Accordingly, the above figures are strictly for information only and not for any other purposes. Shareholders and potential investors are advised not to place undue reliance on the information disclosed herein and to exercise caution when dealing in the securities of the Company. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors. Non-GAAP Disclosure The Company uses non-GAAP measures, such as adjusted profit (loss) from operations (non-GAAP), in evaluating its operating results and for financial and operational decision-making purposes. The Company defines adjusted profit (loss) from operations (non-GAAP) as profit (loss) from operations excluding share-based compensation expenses. By excluding the impact of share-based compensation expenses, which is non-cash in nature, the Company believes that adjusted profit (loss) from operations (non-GAAP) helps identify underlying trends in its business and enhances the overall understanding of the Company’s past performance and future prospects. The Company also believes that the non-GAAP financial measure allows for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making. The non-GAAP financial measure is not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has limitations as analytical tools and when assessing the Company’s operating performance, investors should not consider it in isolation, or as a substitute for, profit from operations prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measure, which should be considered when evaluating the Company’s performance. About NIO Inc. NIO Inc. is a pioneer and a leading company in the global smart electric vehicle market. Founded in November 2014, NIO aspires to shape a sustainable and brighter future with the mission of “Blue Sky Coming.” NIO envisions itself as a user enterprise where innovative technology meets experience excellence. NIO designs, develops, manufactures and sells smart electric vehicles, driving innovations in next-generation core technologies. NIO distinguishes itself through continuous technological breakthroughs and innovations, exceptional products and services, and a community for shared growth. NIO provides premium smart electric vehicles under the NIO brand, family-oriented smart electric vehicles through the ONVO brand, and small smart high-end electric cars with the FIREFLY brand. Safe Harbor Statement This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. NIO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements, circulars or other publications made on the websites of each of The Stock Exchange of Hong Kong Limited (the “SEHK”) and the Singapore Exchange Securities Trading Limited (the “SGX-ST”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIO’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIO’s strategies; NIO’s future business development, financial condition and results of operations; NIO’s ability to develop and manufacture vehicles of sufficient quality and appeal to customers on schedule and on a large scale; its ability to ensure and expand manufacturing capacities including establishing and maintaining partnerships with third parties; its ability to provide convenient and comprehensive power solutions to its customers; the viability, growth potential and prospects of the battery swapping, BaaS, and NIO Assisted and Intelligent Driving and its subscription services; its ability to improve the technologies or develop alternative technologies in meeting evolving market demand and industry development; NIO’s ability to satisfy the mandated safety standards relating to motor vehicles; its ability to secure supply of raw materials or other components used in its vehicles; its ability to secure sufficient reservations and sales of its vehicles; its ability to control costs associated with its operations; its ability to build its current and future brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIO’s filings with the SEC and the announcements and filings on the websites of each of the SEHK and SGX-ST. All information provided in this press release is as of the date of this press release, and NIO does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For more information, please visit: http://ir.nio.com Investor Relations [email protected] Media Relations [email protected] i All translations from RMB to USD for the three months ended December 31, 2025 were made at the rate of RMB6.9931 to US$1.00, the noon buying rate in effect on December 31, 2025 in the H.10 statistical release of the Federal Reserve Board.

NIO Inc. NIO, XPeng Inc. XPEV and Li Auto LI, three major China-based smart electric vehicle manufacturers, recently released their delivery figures for December 2025 and the fourth quarter of 2025. NIO reported a record 48,135 vehicle deliveries in December 2025, marking a 54.6% year-over-year increase. This total included 31,897 units from its premium NIO brand, 9,154 units from the family-focused ONVO brand and 7,084 units from the compact high-end FIREFLY brand. Fourth-quarter deliveries reached a new high of 124,807 vehicles, up 71.7% from the prior year. For full-year 2025, NIO delivered 326,028 vehicles, rising 46.9% year over year, while cumulative deliveries stood at 997,592 units as of Dec. 31, 2025. XPeng delivered 37,508 vehicles in December 2025, representing a modest 2% year-over-year increase. Total deliveries for 2025 surged to 429,445 units, more than doubling from the previous year with a 126% increase. Overseas deliveries for the year totaled 45,008 vehicles, up 96% year over year, as XPeng expanded operations to 60 countries and regions by the end of 2025. Li Auto delivered 44,246 vehicles in December 2025 compared with 58,513 units in the same month of 2024. Fourth-quarter deliveries amounted to 109,194 vehicles, bringing cumulative deliveries to 1,540,215 units as of Dec. 31, 2025. During the year, Li Auto broadened its international presence by launching the Li L9, Li L7 and Li L6 models in Egypt, Kazakhstan and Azerbaijan, marking the entry into markets across Central Asia, the Caucasus and Africa. By year-end, the company operated 548 retail stores in 159 cities, along with 561 service centers and authorized body and paint shops across 224 cities. It also had 3,907 supercharging stations in China, comprising 21,651 charging stalls. While shares of NIO and XPeng have rallied 10.2% and 73.2%, respectively, over the past year, shares of LI have plunged 31.6%. Image Source: Zacks Investment Research NIO, XPEV & LI carry a Zacks Rank #3 (Hold) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIO Inc. (NIO) : Free Stock Analysis Report Li Auto Inc. Sponsored ADR (LI) : Free Stock Analysis Report XPeng Inc. Sponsored ADR (XPEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Company Achieved New Record-High Monthly and Quarterly Deliveries 34,749 vehicles were delivered in September 2025, increasing by 64.1% year-over-year 87,071 vehicles were delivered in the three months ended September 2025, increasing by 40.8% year-over-year Cumulative deliveries reached 872,785 as of September 30, 2025 SHANGHAI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its September and third quarter 2025 delivery results. The Company delivered 34,749 vehicles in September 2025, reaching a new monthly record and representing an increase of 64.1% year-over-year. The deliveries consisted of 13,728 vehicles from the Company’s premium smart electric vehicle brand NIO, 15,246 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO, and 5,775 vehicles from the Company’s small smart high-end electric car brand FIREFLY. The Company delivered 87,071 vehicles in the third quarter of 2025, reaching a new quarterly high and representing an increase of 40.8% year-over-year. Cumulative deliveries reached 872,785 as of September 30, 2025. On September 20, 2025, NIO’s flagship premium SUV, the All-New ES8, was officially launched, with user deliveries starting shortly after. Built upon NIO’s decade-long technological achievements, the All-New ES8 represents the pinnacle of the latest smart EV technologies and is well positioned to lead large three-row SUVs into the battery electric era. Setting a new benchmark for the premium large three-row battery electric SUVs, the All-New ES8 offers users a refined, safe, and seamless experience on every journey towards a new horizon. About NIO Inc. NIO Inc. is a pioneer and a leading company in the global smart electric vehicle market. Founded in November 2014, NIO aspires to shape a sustainable and brighter future with the mission of “Blue Sky Coming”. NIO envisions itself as a user enterprise where innovative technology meets experience excellence. NIO designs, develops, manufactures and sells smart electric vehicles, driving innovations in next-generation core technologies. NIO distinguishes itself through continuous technological breakthroughs and innovations, exceptional products and services, and a community for shared growth. NIO provides premium smart electric vehicles under the NIO brand, family-oriented smart electric vehicles through the ONVO brand, and small smart high-end electric cars with the FIREFLY brand. Safe Harbor Statement This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. NIO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements, circulars or other publications made on the websites of each of The Stock Exchange of Hong Kong Limited (the “SEHK”) and the Singapore Exchange Securities Trading Limited (the “SGX-ST”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIO’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIO’s strategies; NIO’s future business development, financial condition and results of operations; NIO’s ability to develop and manufacture vehicles of sufficient quality and appeal to customers on schedule and on a large scale; its ability to ensure and expand manufacturing capacities including establishing and maintaining partnerships with third parties; its ability to provide convenient and comprehensive power solutions to its customers; the viability, growth potential and prospects of the battery swapping, BaaS, and NIO Assisted and Intelligent Driving and its subscription services; its ability to improve the technologies or develop alternative technologies in meeting evolving market demand and industry development; NIO’s ability to satisfy the mandated safety standards relating to motor vehicles; its ability to secure supply of raw materials or other components used in its vehicles; its ability to secure sufficient reservations and sales of its vehicles; its ability to control costs associated with its operations; its ability to build its current and future brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIO’s filings with the SEC and the announcements and filings on the websites of each of the SEHK and SGX-ST. All information provided in this press release is as of the date of this press release, and NIO does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For more information, please visit: http://ir.nio.com Investor Relations [email protected] Media Relations [email protected]

Two of China’s biggest noted vehicle makers, NIO Inc. NIO and Li Auto LI, are about to report their second-quarter 2025 results. Li Auto will release its numbers this Thursday, while NIO will follow next Tuesday. Ahead of their results, the question is: Which of these two EV players looks better positioned right now? Li Auto has built its success on a hybrid approach. Its extended-range electric vehicles (EREVs) combine EV benefits with the reassurance of a gasoline-powered generator, easing range anxiety for Chinese drivers. The company’s popular L-series — L6, L7, L8 and L9 — has captured strong demand. Li also ventured into pure battery EVs with the MEGA last year, while recently adding the Li i8, a six-seat family SUV, to its lineup. Another model, the Li i6, is expected to debut soon. NIO, on the other hand, has gone all-in on pure EVs. Its portfolio includes a broad range of sedans and SUVs such as the ES6, ES8, EC6, ET5, ET7 and ET9. The company is also set to launch its redesigned ES8 later this year. Beyond the NIO brand, NIO is expanding with ONVO, its mass-market division, which has already launched the L60 and L90, with a third model on the way. Its premium small car brand, Firefly, started deliveries in April. This three-pronged strategy highlights NIO’s ambition to capture different segments of the EV market. In terms of sheer numbers, Li Auto continues to outpace NIO. For the second quarter of 2025, Li delivered 111,074 vehicles, while NIO delivered 72,056. However, the growth picture tells a different story. Li’s deliveries were only up 2.3% year over year, suggesting demand is stabilizing. Meanwhile, NIO’s deliveries surged 25.6% compared to last year, signaling a stronger momentum shift in its favor. Margins are a critical measure of EV makers’ financial health. NIO’s vehicle margin climbed to 10.2% in the first quarter of 2025, an improvement from 9.2% a year ago. The gain was driven by better scale, lower costs per unit and stronger efficiency in its supply chain. Li Auto remains ahead in this metric. Its vehicle margin stood at 19.8% in the first quarter, slightly up from 19.3% in the prior year. The company’s ability to maintain high margins speaks of its cost discipline and pricing power. For now, Li holds the edge on profitability. The balance sheet comparison tilts in Li Auto’s favor. As of March 31, 2025, Li Auto held about $15.3 billion in cash, giving it ample resources to fund research, innovation and expansion. NIO’s cash position was 3.6 billion, far smaller in scale. Additionally, NIO’s long-term debt-to-capitalization ratio is 75%, while Li Auto’s is just 10.8%. This makes Li Auto far less leveraged and financially sturdier. Image Source: Zacks Investment Research The real face-off between the two lies in their technological visions. NIO’s big bet is its battery swap network, part of its Battery-as-a-Service model. This allows drivers to swap out depleted batteries for fully charged ones in just minutes. With more than 3,400 swap stations and more than 26,000 chargers already installed, NIO is building a network that could become a game-changer in EV adoption. The company is even constructing a new facility in Wuhan, with plans to roll out 1,000 new swap stations annually. Li Auto is focused on autonomous driving. Its Li AD Max and Pro systems already support advanced urban and highway navigation. Powered by NVIDIA chips, the company is pushing toward level-4 autonomy. Management has even hinted at developing humanoid robots after it achieves that milestone. While futuristic, Li’s current ADAS features already provide safety and convenience, making autonomy a core strength. Stock performance paints another interesting contrast. Over the past six months, NIO shares have risen 27%, reflecting renewed optimism around its growth prospects. Meanwhile, Li Auto stock has fallen 25%, weighed down by slowing delivery growth and cautious sentiment. Image Source: Zacks Investment Research Valuation adds another layer. Both stocks trade at relatively low forward price-to-sales ratios compared to their five-year averages, but NIO trades at a lower multiple than Li. That makes NIO more attractively valued at current levels. Image Source: Zacks Investment Research NIO appears to have the stronger growth runway. The Zacks Consensus Estimate for NIO’s sales suggests growth of 50% in 2025 and another 36% in 2026. Its bottom line is also projected to improve meaningfully, with the loss expected to narrow 32.5% this year and 68.2% next year. Li Auto’s forecasts are more tempered. Sales are projected to grow just 6% in 2025 before accelerating to 36% in 2026. Its 2025 earnings are expected to decline 13% before rebounding with a 61% jump in 2026. On top of that, recent analyst revisions have trended upward for NIO, while Li has seen downward revisions — a sign of growing confidence in NIO and more cautious sentiment toward Li. Both NIO and Li Auto have carved out unique strengths in China’s EV market. Li Auto’s extended-range EVs, strong balance sheet and higher margins make it a stable player in the industry. However, slowing delivery growth and a Zacks Rank #5 (Strong Sell) raise concerns about its near-term prospects. NIO, on the other hand, is showing accelerating deliveries, strong growth forecasts and a more attractive valuation. Its battery swap strategy and expanding multi-brand portfolio also give it powerful long-term catalysts. With a Zacks Rank #3 (Hold) and upward earnings revisions, NIO looks better positioned than Li Auto heading into the earnings season. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIO Inc. (NIO) : Free Stock Analysis Report Li Auto Inc. Sponsored ADR (LI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver predictive power was shown to be 87.5% for a set of challenging liver toxicity cases – inclusive of classic cases of “liver tox misses” drugs with unforeseen liver toxicity found in clinical trials or drugs that were withdrawn from the market after liver toxicity issues emerged later. The platform identified correctly that 87.5% of the known liver-toxic drugs could be seen as liver toxic using NAMkind™ liver. This is known as the sensitivity of the platform, which at 87.5% is a world’s best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform. VivoSim’s NAMkind™ liver model is a physical organoid wet lab model of liver made using cells from human donors. VivoSim is also developing what it believes will be industry-best in silico predictions of liver tox. Artificial intelligence (AI) models in VivoSim’s NAMkind™ services suite will be trained on extensive set of proprietary, real-world data from organoid models made from human donor cells, giving much richer and more extensive information than is possible with data from human clinical trials. VivoSim offers liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA’s push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim’s market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound. VivoSim has the capability to help transform the way drug development is done. By substantially reducing failures in clinical trials, the company believes it can help reduce the cost of development per approved drug by 50% across the industry. As a result of the inability to fully predict liver toxicity, a number of drugs today still fail clinical trials at late stages or are pulled from the market after launch due to unforeseen liver toxicity. VivoSim believes it will cut the incidence of such events by 50% or more. VivoSim’s NAMkind™ intestine models can also deliver readouts on endpoints that are today not available to industry scientists selecting from many candidate drug molecules. As a result of the lack of such tools, a cancer patient might suffer nausea, vomiting, or intestinal problems, or a patient’s needed chemotherapy dose might be lower than it could be due to such conditions. VivoSim aims to provide transformative solutions for these challenges. The FDA has laid out ambitious goals to phase out animal testing requirements as much as possible. VivoSim is launching to fill in the much-needed gap in commercially available solutions. The technology exists to achieve according to FDA Commissioner Marty A. Makary’s vision, which he expressed in March 2025 with the rollout of FDA’s push to move away from animal testing and towards NAM models. “By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices,” Makary noted. By leveraging AI-based computational modeling, human organ model-based lab testing, and. VivoSim is delivering on the promise of this technology, and will use its proprietary methods and cutting-edge capabilities for NAMkind models that displace use of animals and provide superior outcomes for its pharmaceutical customers, ultimately delivering for on the end goal of providing better solutions for patients. Forward Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s belief that it is developing an industry-best in silico predictions of liver tox, that it can help reduce the cost of development per approved drug by 50% across the industry and that it can cut the incidence of drugs failing clinical trial at late stages or being pulled from the market after launch due to unforeseen liver toxicity by 50% or more, the Company’s expectations about its AI models in the Company’s NAMkind™ services suite, the Company’s capability to help transform the way drug development is done, the Company’s plan to provide transformative solutions for certain challenges, including that a cancer patient might suffer nausea, vomiting, or intestinal problems, or a patient’s needed chemotherapy dose might be lower than it could be and the Company’s expectations that it can provide superior outcomes for its pharmaceutical customers and better solutions for patients. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. Contact Investor Relations [email protected]